The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch
July 24, 2023 09:00 ET
|
Molecure
Press release The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch Molecure can proceed with clinical...
Molecure completes successful Secondary Public Offering (SPO) of approximately PLN 50 million (USD 12 million) with proceeds to be used to fund and build a first in class, sustainable pipeline of breakthrough therapies
July 21, 2023 03:00 ET
|
Molecure
Press release Molecure completes successful Secondary Public Offering (SPO) of approximately PLN 50 million (USD 12 million) with proceeds to be used to fund and build a first in class, sustainable...
Molecure Files an Investigational New Drug (IND) application for lead clinical candidate OATD-01 with U.S. FDA ahead of a planned Phase 2 pulmonary sarcoidosis study
June 23, 2023 03:00 ET
|
Molecure
OATD-01 is a first in class chitotriosidase 1 (CHIT1) inhibitor with disease modifying potential in sarcoidosis and other interstitial lung diseasesClearance of the IND application will pave the way...
Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress
March 30, 2023 03:00 ET
|
Molecure
Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress Entering 2023 with strong momentum and a robust pipeline of proprietary, first-in-class compoundsFirst...
Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer
March 08, 2023 09:00 ET
|
Molecure
Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer OATD-02 is an oral, potent and selective dual arginase...